Gampala, Silpa
Shah, Fenil
Lu, Xiaoyu
Moon, Hye-ran
Babb, Olivia
Umesh Ganesh, Nikkitha
Sandusky, George
Hulsey, Emily
Armstrong, Lee
Mosely, Amber L.
Han, Bumsoo
Ivan, Mircea
Yeh, Jing-Ruey Joanna
Kelley, Mark R.
Zhang, Chi
Fishel, Melissa L. http://orcid.org/0000-0002-9436-6382
Funding for this research was provided by:
dod peer reviewed cancer research program (NF180045)
National Cancer Institute (R01CA167291, R01CA167291, R01CA167291-S1, R01CA167291-S1, R01CA205166, R01CA231267, R01HL140961, R01CA211098, P30 CA082709, P30 CA082709, P30 CA023168)
National Heart, Lung, and Blood Institute (U01HL143403, U01 HL143403)
Indiana Clinical and Translational Sciences Institute (UL1 TR002529, UL1 TR002529)
National Institute of General Medical Sciences (1R01GM131399)
national institutes of health (R01CA215410)
Article History
Received: 29 November 2020
Accepted: 18 July 2021
First Online: 10 August 2021
Declarations
:
: All animal studies were conducted under the guidelines of the National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine.
: Not applicable.
: Mark R. Kelley has licensed APX3330 through Indiana University Research and Technology Corporation to Apexian Pharmaceuticals LLC. APX2009 and APX2014 are second generation compounds from Apexian Pharmaceuticals. Apexian Pharmaceuticals had neither control nor oversight of the studies, interpretation, or presentation of the data in this manuscript.